BioNTech (NASDAQ: BNTX) director discloses holding of 400 Ordinary Shares

Rhea-AI Filing Summary

BioNTech SE director Rudolf Staudigl filed an initial ownership report showing he holds 400 Ordinary Shares of the company. These shares are reported as held directly, and the filing does not list any recent purchase, sale, or other transaction activity, only the existing position.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Staudigl Rudolf

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	400	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Humza Bokhari, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Rudolf Staudigl’s Form 3 filing for BioNTech (BNTX) show?

The Form 3 shows Rudolf Staudigl, a director of BioNTech SE, reporting beneficial ownership of 400 Ordinary Shares. It is an initial disclosure of his holdings and does not describe any recent trades or changes in his position.

How many BioNTech (BNTX) shares does director Rudolf Staudigl report owning?

Rudolf Staudigl reports owning 400 Ordinary Shares of BioNTech SE. These shares are listed as directly held, giving investors a baseline view of his equity stake at the time of this initial ownership report.

Is Rudolf Staudigl’s BioNTech (BNTX) stake held directly or indirectly?

Rudolf Staudigl’s reported BioNTech stake is held directly. The Form 3 classifies his ownership type as direct, meaning the 400 Ordinary Shares are not reported through a trust, partnership, or other intermediary entity.

Does the BioNTech (BNTX) Form 3 for Rudolf Staudigl include any recent trades?

No, the Form 3 does not include recent trades. It records a holding entry for 400 Ordinary Shares, serving as an initial statement of beneficial ownership rather than a report of purchases or sales.

What role does Rudolf Staudigl have at BioNTech (BNTX)?

Rudolf Staudigl is identified as a director of BioNTech SE in the Form 3. Directors are required to disclose their shareholdings, and this filing provides his initial reported stake of 400 Ordinary Shares in the company.